Protirelin Tartrate Injection 2mg/1mL “NP” (Protirelin Tartrate Injection “NP”® / プロチレリン酒石酸塩注2mg「NP」)

JPY ¥23,000

Japanese Prolonged Disturbance of Consciousness / Spinocerebellar Degeneration Treatment Agent (Protirelin Tartrate Hydrate 2mg/1mL). For intravenous or intramuscular injection. 1mL x 10 ampoules. Mfd. by Nipro Corporation, Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥21,160
10 - 19 12% JPY ¥20,240
20 + 18% JPY ¥18,860
SKU: PRT-2-INJ Category:

Description

Product Overview / 商品概要

Protirelin Tartrate Injection 2mg/1mL “NP” (プロチレリン酒石酸塩注2mg「NP」)
Generic: Protirelin Tartrate Hydrate / プロチレリン酒石酸塩水和物
Therapeutic Category: Prolonged Disturbance of Consciousness Treatment Agent / Spinocerebellar Degeneration Treatment Agent / 遷延性意識障害治療剤・脊髄小脳変性症治療剤
Manufactured by: Nipro Corporation / ニプロ株式会社

Composition & Specification / 組成・規格

Active Ingredient: Protirelin Tartrate Hydrate (JP) 2.928mg (equivalent to Protirelin 2mg) per 1 ampoule (1mL) / 1アンプル(1mL)中 日本薬局方 プロチレリン酒石酸塩水和物 2.928mg(プロチレリンとして2mg)
Additives: D-Sorbitol 50mg, Hydrochloric acid q.s., Sodium hydroxide q.s. / D-ソルビトール 50mg、塩酸 適量、水酸化ナトリウム 適量
Appearance: Colorless clear solution; pH 5.5–6.5; osmotic pressure ratio approximately 1 (relative to normal saline)
外観: 無色澄明の液、pH 5.5〜6.5、浸透圧比 約1(生理食塩液に対する比)

Indications / 効能効果

EN: Prolonged disturbance of consciousness (excluding coma and semicoma) associated with the following conditions: head trauma; subarachnoid hemorrhage (only when the period of fixed consciousness disturbance is within 3 weeks). Improvement of ataxia in spinocerebellar degeneration.
JA: ○下記疾患に伴う昏睡、半昏睡を除く遷延性意識障害・頭部外傷・くも膜下出血、ただし、意識障害固定期間3週以内○脊髄小脳変性症における運動失調の改善

Dosage and Administration / 用法用量

EN: Prolonged disturbance of consciousness (excluding coma and semicoma): Administer once daily for 10 days by intravenous injection or intravenous drip infusion. For intravenous injection, dilute in 5–10mL of normal saline, glucose injection, or water for injection and inject slowly. 1) Head trauma: 0.732–2.92mg as protirelin tartrate hydrate (0.5–2mg as protirelin) per dose. 2) Subarachnoid hemorrhage (fixed consciousness disturbance period within 3 weeks): 2.92mg as protirelin tartrate hydrate (2mg as protirelin) per dose. Spinocerebellar degeneration: Administer 0.732–2.92mg as protirelin tartrate hydrate (0.5–2mg as protirelin) once daily by intramuscular or intravenous injection; in severe cases, 2.92mg as protirelin tartrate hydrate (2mg as protirelin). Administer daily for 2–3 weeks, then allow a 2–3 week drug-free interval; repeat thereafter, or administer intermittently 2–3 times per week. For intravenous injection, dilute in 5–10mL of normal saline, glucose injection, or water for injection and inject slowly.
JA: 〈遷延性意識障害の場合(ただし、昏睡、半昏睡を除く)〉通常、成人には疾患に応じて、下記の用量を1日1回10日間静注又は点滴静注する。静脈内注射の場合は、生理食塩液、ブドウ糖注射液又は注射用水5〜10mLに希釈して、徐々に注射する。1)頭部外傷:1回プロチレリン酒石酸塩水和物として0.732〜2.92mg(プロチレリンとして0.5〜2mg)2)くも膜下出血(ただし、意識障害固定期間3週以内):1回プロチレリン酒石酸塩水和物として2.92mg(プロチレリンとして2mg)〈脊髄小脳変性症の場合〉通常、成人には1日1回プロチレリン酒石酸塩水和物として0.732〜2.92mg(プロチレリンとして0.5〜2mg)を筋肉内又は静脈内に注射するが、重症例にはプロチレリン酒石酸塩水和物として2.92mg(プロチレリンとして2mg)を注射する。2〜3週間連日注射した後、2〜3週間の休薬期間をおく。以後、これを反復するか、週2〜3回の間歇注射を行う。静脈内注射の場合は、生理食塩液、ブドウ糖注射液又は注射用水5〜10mLに希釈して、徐々に注射する。

Contraindications / 禁忌

EN:
JA:

Regulatory Information / 規制情報

Approval No.: 22500AMX00809
Sales Started: July 1997 / 1997年7月
Classification Code: 87119
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 1mL x 10 ampoules / 1mL×10管[アンプル]
Other Available Packages (by special order): 1mL x 10 ampoules

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Protirelin Tartrate Injection 2mg/1mL “NP” (Protirelin Tartrate Injection “NP”® / プロチレリン酒石酸塩注2mg「NP」)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Protirelin Tartrate Injection 2mg

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.